PARP Inhibitors for Patients with Hormone-Sensitive and Castration-Resistant Metastatic Prostate Cancer — An Interview with Dr Wassim Abida

Dr Wassim Abida from Memorial Sloan Kettering Cancer Center in New York, New York, discusses the role of PARP inhibitors in the management of hormone-sensitive and castration-resistant metastatic prostate cancer.

CME information and select publications here.